Changes of Brain Glucose Metabolism in the Pretreatment Patients with Non-Small Cell Lung Cancer: A Retrospective PET/CT Study

PLoS One. 2016 Aug 16;11(8):e0161325. doi: 10.1371/journal.pone.0161325. eCollection 2016.

Abstract

Objective: The tumor-to-brain communication has been emphasized by recent converging evidences. This study aimed to compare the difference of brain glucose metabolism between patients with non-small cell lung cancer (NSCLC) and control subjects.

Methods: NSCLC patients prior to oncotherapy and control subjects without malignancy confirmed by 6 months follow-up were collected and underwent the resting state 18F-fluoro-D-glucose (FDG) PET/CT. Normalized FDG metabolism was calculated by a signal intensity ratio of each brain region to whole brain. Brain glucose metabolism was compared between NSCLC patients and control group using two samples t-test and multivariate test by statistical parametric maps (SPM) software.

Results: Compared with the control subjects (n = 76), both brain glucose hyper- and hypometabolism regions with significant statistical differences (P<0.01) were found in the NSCLC patients (n = 83). The hypermetabolism regions (bilateral insula, putamen, pallidum, thalamus, hippocampus and amygdala, the right side of cerebellum, orbital part of right inferior frontal gyrus and vermis) were component parts of visceral to brain signal transduction pathways, and the hypometabolism regions (the left superior parietal lobule, bilateral inferior parietal lobule and left fusiform gyrus) lied in dorsal attention network and visuospatial function areas.

Conclusions: The changes of brain glucose metabolism exist in NSCLC patients prior to oncotherapy, which might be attributed to lung-cancer related visceral sympathetic activation and decrease of dorsal attention network function.

MeSH terms

  • Biological Transport
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain / metabolism*
  • Brain / radiation effects
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Case-Control Studies
  • Female
  • Fluorodeoxyglucose F18
  • Glucose / metabolism*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography*
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18
  • Glucose

Grants and funding

This study has received funding by the National Natural Science Foundation of China (No. 81171317, 81471631), New Century Excellent Talent Support Plan from Ministry of Education of China (NCET-11-0438), and Fund of the First Affiliated Hospital of Xi'an Jiaotong University (2014YK22). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.